Screening and management of metabolic, cardiac, and bone health in prostate cancer patients on androgen deprivation therapy A survey of specialized physicians.
作者信息
Nguyen David-Dan, Mousa Ahmad, Klotz Laurence, Niazi Tamim, Pouliot Frédéric, Kokorovic Andrea, Lavallée Luke T, Huynh Melissa, Lapointe Nathalie, Di Risio Michelle, Wallis Christopher J D
机构信息
Division of Urology, Department of Surgery, University of Toronto, Toronto, ON, Canada.
Division of Urology, Department of Surgery, Sunnybrook Health Sciences, University of Toronto, ON, Canada.
出版信息
Can Urol Assoc J. 2024 Jun;18(6):212-215. doi: 10.5489/cuaj.8687.
Abstract
摘要
相似文献
1
Screening and management of metabolic, cardiac, and bone health in prostate cancer patients on androgen deprivation therapy A survey of specialized physicians.
Can Urol Assoc J. 2024 Jun;18(6):212-215. doi: 10.5489/cuaj.8687.
2
Bone health in men receiving androgen deprivation therapy for prostate cancer.
J Urol. 2007 Jan;177(1):17-24. doi: 10.1016/j.juro.2006.08.089.
3
Metabolic changes in patients with prostate cancer during androgen deprivation therapy.
Int J Urol. 2018 Jan;25(1):45-53. doi: 10.1111/iju.13473. Epub 2017 Oct 20.
4
Metabolic and cardiovascular risks of androgen-deprivation therapy for prostate cancer.
Expert Rev Endocrinol Metab. 2010 Jul;5(4):531-537. doi: 10.1586/eem.10.35.
5
Relationship between circulating FSH levels and body composition and bone health in patients with prostate cancer who undergo androgen deprivation therapy: The BLADE study.
Elife. 2024 Apr 24;13:e92655. doi: 10.7554/eLife.92655.
6
Background to and management of treatment-related bone loss in prostate cancer.
Drugs Aging. 2002;19(12):899-910. doi: 10.2165/00002512-200219120-00002.
7
Higher serum alkaline phosphatase value indicates the need for bone mineral density testing in non-metastatic prostate cancer patients undergoing androgen deprivation therapy.
Jpn J Clin Oncol. 2022 Jan 3;52(1):73-80. doi: 10.1093/jjco/hyab147.
8
Short-term impact of androgen deprivation therapy on bone strength in castration-sensitive prostate cancer.
Int J Urol. 2019 Oct;26(10):980-984. doi: 10.1111/iju.14077. Epub 2019 Jul 28.
9
Bone health effects of androgen-deprivation therapy and androgen receptor inhibitors in patients with nonmetastatic castration-resistant prostate cancer.
Prostate Cancer Prostatic Dis. 2021 Jun;24(2):290-300. doi: 10.1038/s41391-020-00296-y. Epub 2020 Oct 7.
10
A Review on the Effects of Androgen Deprivation Therapy (ADT) on Bone Health Status in Men with Prostate Cancer.
Endocr Metab Immune Disord Drug Targets. 2017 Nov 16;17(4):276-284. doi: 10.2174/1871530317666170919112757.
引用本文的文献
1
The Effect of Androgen Deprivation Therapy on the Cardiovascular System in Advanced Prostate Cancer.
Medicina (Kaunas). 2024 Oct 22;60(11):1727. doi: 10.3390/medicina60111727.
2
Metabolic, cardiac, and bone health testing in patients with prostate cancer on androgen-deprivation therapy: A population-based assessment of adherence to therapeutic monitoring guidelines.
Cancer. 2025 Jan 1;131(1):e35606. doi: 10.1002/cncr.35606. Epub 2024 Oct 13.
本文引用的文献
1
Urologic Oncology Survivorship Guidelines: An Overview of the Evidence and the Current Implementation Gap.
Eur Urol Focus. 2023 May;9(3):431-434. doi: 10.1016/j.euf.2023.02.006. Epub 2023 Feb 25.
2
UPDATE - Canadian Urological Association guideline on androgen deprivation therapy: Adverse events and management strategies.
Can Urol Assoc J. 2022 Aug;16(8):E416-E431. doi: 10.5489/cuaj.8054.
3
Optimizing screening and management of cardiovascular health in prostate cancer: A review.
Can Urol Assoc J. 2020 Sep;14(9):E458-E464. doi: 10.5489/cuaj.6685.
4
Cardiovascular and Skeletal-related Events Following Localized Prostate Cancer Treatment: Role of Surgery, Radiotherapy, and Androgen Deprivation.
Urology. 2016 Nov;97:145-152. doi: 10.1016/j.urology.2016.08.002. Epub 2016 Aug 5.
5
Statin Use at the Time of Initiation of Androgen Deprivation Therapy and Time to Progression in Patients With Hormone-Sensitive Prostate Cancer.
JAMA Oncol. 2015 Jul;1(4):495-504. doi: 10.1001/jamaoncol.2015.0829.
6
Adverse effects of androgen deprivation therapy and strategies to mitigate them.
Eur Urol. 2015 May;67(5):825-36. doi: 10.1016/j.eururo.2014.07.010. Epub 2014 Aug 2.
7
Metformin use and all-cause and prostate cancer-specific mortality among men with diabetes.
J Clin Oncol. 2013 Sep 1;31(25):3069-75. doi: 10.1200/JCO.2012.46.7043. Epub 2013 Aug 5.
8
What do prostate cancer patients die of?
Oncologist. 2011;16(2):175-81. doi: 10.1634/theoncologist.2010-0338. Epub 2011 Jan 21.
Zotero 插件